Related Experiment Video
Updated: Dec 27, 2025
Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
Published on: December 27, 2017
Human megakaryocytic microparticles induce de novo platelet biogenesis in a wild-type murine model
Christian Escobar1, Chen-Yuan Kao2,3, Samik Das2,3
1Department of Biological Sciences.
Abstract:
Platelet transfusions are used to treat idiopathic or drug-induced thrombocytopenia. Platelets are an expensive product in limited supply, with limited storage and distribution capabilities because they cannot be frozen. We have demonstrated that, in vitro, human megakaryocytic microparticles (huMkMPs) target human CD34+ hematopoietic stem and progenitor cells (huHSPCs) and induce their Mk differentiation and platelet biogenesis in the absence of thrombopoietin. In this study, we showed that, in vitro, huMkMPs can also target murine HSPCs (muHSPCs) to induce them to differentiate into megakaryocytes in the absence of thrombopoietin. Based on that, using wild-type BALB/c mice, we demonstrated that intravenously administering 2 × 106 huMkMPs triggered de novo murine platelet biogenesis to increase platelet levels up to 49% 16 hours after administration. huMkMPs also largely rescued low platelet levels in mice with induced thrombocytopenia 16 hours after administration by increasing platelet counts by 51%, compared with platelet counts in thrombocytopenic mice. Normalized on a tissue-mass basis, biodistribution experiments show that MkMPs localized largely to the bone marrow, lungs, and liver 24 hours after huMkMP administration. Beyond the bone marrow, CD41+ (megakaryocytes and Mk-progenitor) cells were frequent in lungs, spleen, and especially, liver. In the liver, infused huMKMPs colocalized with Mk progenitors and muHSPCs, thus suggesting that huMkMPs interact with muHSPCs in vivo to induce platelet biogenesis. Our data demonstrate the potential of huMkMPs, which can be stored frozen, to treat thrombocytopenias and serve as effective carriers for in vivo, target-specific cargo delivery to HSPCs.
Insights
Human megakaryocytic microparticles (huMkMPs) can stimulate platelet production in mice, offering a potential alternative to transfusions for treating thrombocytopenia. These microparticles can be stored frozen and target hematopoietic stem cells for platelet biogenesis.
Area of Science:
- Hematology
- Cell Biology
- Biotechnology
Background:
- Platelet transfusions are critical for treating thrombocytopenia but face limitations due to cost, supply, and storage challenges.
- Existing treatments for thrombocytopenia are hampered by the inability to freeze platelets, impacting their availability and distribution.
- Human megakaryocytic microparticles (huMkMPs) have shown in vitro potential to induce platelet production from hematopoietic stem and progenitor cells (HSPCs).
Purpose of the Study:
- To investigate the efficacy of human megakaryocytic microparticles (huMkMPs) in inducing platelet biogenesis in vivo.
- To assess the therapeutic potential of huMkMPs in treating thrombocytopenia in a murine model.
- To determine the biodistribution and target engagement of huMkMPs in vivo.
Main Methods:
- In vitro studies confirmed huMkMPs' ability to induce megakaryocyte differentiation and platelet production from murine HSPCs (muHSPCs) without thrombopoietin.
- Intravenous administration of huMkMPs to wild-type BALB/c mice to assess de novo platelet biogenesis.
- Induced thrombocytopenia model in mice to evaluate huMkMP's rescue effect on platelet levels.
- Biodistribution studies using normalized tissue-mass analysis and CD41+ cell identification to track huMkMP localization and interaction with HSPCs.
Main Results:
- Administration of huMkMPs significantly increased platelet levels by up to 49% in healthy mice within 16 hours.
- huMkMPs effectively rescued low platelet counts in mice with induced thrombocytopenia, increasing levels by 51%.
- Biodistribution studies showed huMkMPs localized primarily to the bone marrow, lungs, and liver, with evidence of interaction with murine HSPCs in the liver.
Conclusions:
- Human megakaryocytic microparticles (huMkMPs) can effectively induce platelet biogenesis and increase platelet counts in vivo.
- huMkMPs demonstrate therapeutic potential for treating thrombocytopenias and can be stored frozen, overcoming limitations of current platelet therapies.
- huMkMPs show promise as targeted delivery vehicles for HSPCs, facilitating platelet production and potentially other therapeutic applications.
